Introduction
One of the most significant risk factors for melanoma is a family history of the disease. It is estimated that approximately 10% of melanoma cases report a first-or second-degree relative with melanoma. The CDKN2A locus accounts for susceptibility in 25-40% of melanoma families (Hayward, 2000) , whereas mutations in the CDK4 gene have to date been documented in only three melanoma-prone kindreds (Zuo et al., 1996; Soufir et al., 1998) . These two genes encode p16 and cyclin-dependent kinase 4, respectively, proteins that function in the same cell-cycle regulatory pathway, namely that of the pRb-regulated G1 to S phase transition. Activating mutations in CDK4 are oncogenic, since this kinase negatively regulates pRb by phosphorylation, thereby causing it to release transcription factors of the E2F family. In contrast, p16 is a tumour suppressor and normally functions to inhibit the kinase activity of CDK4. Mutations of CDKN2A and CDK4 are rare but clearly highly penetrant. Other high-penetrance melanoma predisposition genes are likely to exist and those that encode proteins involved in cell-cycle regulation will be strong candidates. This review will discuss the current state of play regarding CDKN2A and CDK4, efforts to map other high-penetrance susceptibility genes, the involvement of pigmentation genes acting both as low penetrance and modifier genes, and the role of ultraviolet radiation (UVR) in modifying melanoma risk.
High penetrance genes

CDKN2A
In the 8 years since the CDKN2A gene was identified as the first high-penetrance melanoma susceptibility gene there have been numerous reports of germline mutations occurring in melanoma-prone families or in melanoma cases selected because of young age or multiple primary tumours. These findings will not be summarized here, instead, readers are urged to peruse several excellent reviews that comprehensively document both germline and somatic mutations in CDKN2A (Smith-Sorensen and Hovig, 1996; Foulkes et al., 1997; Ruas and Peters, 1998) . The present review will focus on some of the salient points relating to CDKN2A that have emerged from the literature over the past few years.
The incidence of germline CDKN2A mutations in the general population is exceedingly low. In a populationbased study of melanoma cases from Queensland, Australia, Aitken et al. (1999) estimated that just 0.2% of all melanoma cases are caused by CDKN2A mutations. Given that the lifetime risk of developing melanoma in Queensland is approximately 1 : 15-1 : 20 (MacLennan et al., 1992) this can be extrapolated to impute that B1 : 10 000 of the general population of Queensland are germline CDKN2A mutation carriers. Even population-based series of young melanoma patients have shown a very low frequency of CDKN2A mutations. In a study of children aged less than 15 years with melanoma only 1/31 cases tested carried a CDKN2A mutation and this individual had a strong family history of melanoma (Whiteman et al., 1997) . Similarly, screening of a cohort of 147 adolescents aged 15-19 years with melanoma found mutations in only two cases (Youl et al., 2002) , and in a clinic-based series of melanoma cases younger than 40 years of age, 1/49 patients was found to carry a mutation and this individual had a very strong family history of the disease (Tsao et al., 2000) . In another group that one would expect to be more genetically predisposed to melanoma, namely cases that have developed more than one primary tumour, the mutation frequency has also proved to be relatively low. The results from four major studies are remarkably consistent, with values ranging from 9 to 15%, but once again many of the mutationpositive cases had documented family history of melanoma (Table 1) .
Wherever recurrent mutations in CDKN2A have been analysed, they have been shown to be because of a common founder (Table 2 and references therein), with the exception of the 33ins24 mutation that has presumably arisen multiple times because of DNA polymerase slippage over a 24 basepair repeat region (Pollock et al., 1998) .
Given that somatic mutations in CDKN2A have been documented in a wide variety of different tumour types (Smith-Sorensen and Hovig, 1996; Foulkes et al., 1997; Ruas and Peters, 1998) attention has focused on the possible contribution of germline CDKN2A mutations to risk of nonmelanoma cancers in individuals from mutation-positive families. The first evidence of a broader tumour spectrum in melanoma-prone kindreds was the report of an increased risk of pancreatic cancer in families with CDKN2A mutations (Goldstein et al., 1995) . There occurred seven cases of pancreatic cancer in 4/10 families carrying a mutation, versus 0.32 cases expected, which equates to a 21.8-fold relative risk of this tumour type in individuals with a germline CDKN2A mutation. At the same time, Whelan et al. (1995) reported a CDKN2A mutation in a kindred with three cases of pancreatic cancer and two cases of melanoma, and suggested that CDKN2A may underlie susceptibility to the familial cancer syndrome comprising these tumour types. Several other groups have since reported the occurrence of pancreatic cancer in mutation-positive melanoma families (Gruis et al., 1995; Borg et al., 1996 Borg et al., , 2000 Ciotti et al., 1996; Moskaluk et al., 1998; Soufir et al., 1998; Ghiorzo et al., 1999; Liu et al., 1999; Goldstein et al., 2000; Lal et al., 2000a, b; Lynch et al., 2002) . There have also been suggestions of an increased risk of breast, prostate, colon and lung cancers, but these are the most common of all cancers and therefore their occurrence in melanoma families may be because of chance. We await a large collaborative study from the International Melanoma Genetics Consortium to document risks of nonmelanoma cancers in families segregating CDKN2A mutations. However, anecdotally there appears to be an elevated risk of oral squamous cell carcinomas (SCCs) suggesting that melanoma in concert with head and neck SCCs may constitute a little recognized tumour syndrome similar to the melanoma-pancreatic cancer syndrome (Table 3 and references therein).
CDK4
Worldwide, only three families have been reported to carry mutations of CDK4. Interestingly, all mutations occur in codon 24, with two families carrying an R24C change (Zuo et al., 1996) and another having an R24H substitution (Soufir et al., 1998) . The clustering of mutations within the same codon indicates the importance of this residue in some of the functional properties of CDK4. The arginine normally at this position is critical in allowing p16 to bind to the kinase, hence substitutions of this amino acid abrogate the capacity for p16 to associate with and inactivate CDK4. Since the activities of CDK4 and p16 both affect the same downstream effectors (pRb and the genes regulated by the E2F transcription factors) it is not surprising that clinical characteristics such as mean age of diagnosis of melanoma, mean number of melanomas and number of nevi are indistinguishable between CDKN2A mutation- Yarbrough et al. (1996) Tongue and tonsillar pillar Platz et al. (1997) Tongue; nasopharynyx; oesophagus; larynx Puig et al. 
ARF
Since melanoma appears to segregate with chromosome 9p markers in a far greater proportion of families than have been shown to carry mutations of CDKN2A, it has long been speculated that this high degree of linkage to 9p might indicate the presence of another melanoma susceptibility gene in this region. One of the prime candidates for such a gene is p14ARF (p19ARF in mouse), the product of an alternative transcript arising from the CDKN2A locus. Currently, the CDKN2A locus is unique in the mammalian genome in that it gives rise to two completely unrelated proteins through alternative splicing and translation of the products in different reading frames. The INK4A and ARF mRNAs are transcribed from different first exons but utilize the same second and third exons (Figure 1 ). CDKN2A germline mutations in exon 1a affect only the INK4A transcript, whereas some of those occurring in exon 2 can affect both INK4A and ARF. Like p16, p14ARF is also a tumour suppressor protein but acts through a different pathway, which involves stabilization of p53 through abrogation of HDM2 (Mdm2 in mouse)-induced p53 degradation (Zhang et al., 1998) . Recent evidence has accumulated to indicate that ARF mutations independently predispose to melanoma, as well as nervous system tumours (NSTs). Interestingly, this combination of tumours has been proposed as a discrete syndrome (OMIM 155755) by several investigators (Kaufman et al., 1993; Azizi et al., 1995; Bahuau et al., 1997) . The first documented individual to carry a constitutional deletion of part of chromosome 9p, because of an unbalanced chromosome translocation, developed multiple melanomas and a plexiform neurofibroma (Petty et al., 1993) . It was estimated that the deletion in this patient spanned at least 6 megabases of DNA and rendered the CDKN2A, ARF and CDKN2B loci hemizygous. Several years later, Bahuau et al. (1998) reported two families with melanoma and a range of NSTs (including astrocytoma, meningioma, schwanomma and neurofibroma) that also carried hemizygous deletions of part of chromosome 9p. In one family it was concluded that the deletion encompassed the same three loci that were deleted in the translocation patient and in the other family just the CDKN2A and ARF genes were deleted. However, the assumed order of some of the microsatellite markers (specifically D9S974 and D9S958) on which the deletion boundaries in these families were based was later found to be incorrect (Randerson-Moor et al., 2001) . Reinterpretation of the deletions in the light of the corrected marker order indicates that both families carry a deletion of the ARF locus and the family with the larger deletion also has lost one copy of CDKN2B, but whether the CDKN2A locus remains unaltered in these kindreds is uncertain -it may or may not be deleted in both families and awaits follow-up assessment by quantitative PCR or analysis of SNPs within the coding region of CDKN2A. Notably, if both copies of CDKN2A were present in the family with the smaller deletion it would provide strong evidence for the tumour spectrum being due soley to deletion of ARF. Additional support for p14ARF inactivation being responsible, at least in part, for predisposition to NSTs and melanoma comes from Petronzelli et al. (2001) who reported a family in which there were nine melanoma cases, four of whom also developed neurofibromas. This family carries a germline splicing mutation that results in a lack of exon 2 sequences being encoded in either p16 or p14ARF, thus both proteins are defective.
The first unequivocal report of a germline deletion of ARF in the absence of a concomitant loss of either CDKN2A or CDKN2B was found in another family segregating melanomas and NSTs (Randerson-Moor et al., 2001) . This family included four melanoma cases, one of whom also developed a neurilemmoma in the chest wall.
Another effective deletion specifically of ARF has been reported recently by Hewitt et al. (2002) who describe a family in which a mother and daughter with melanoma carry a mutation of the terminal nucleotide of exon 1b. This substitution would be expected to give rise to replacement of a glycine with an arginine residue in p14ARF; however, it was found that this mutation also affects the splicing of the ARF mRNA and leads to complete absence of the mutant transcript and hence haploinsufficiency for p14ARF. In this family, there were three other individuals with breast cancer (at least one of whom carries the mutation) but no documented NSTs.
To date, a solitary germline intragenic mutation specifically affecting ARF has been documented in a patient with multiple melanomas but without family history of melanoma or NSTs (Rizos et al., 2001) . In this individual, an insertion of 16 base pairs within exon 1b gives rise to a frameshift in p14ARF (but leaves p16 intact) and leads to the inactivation of the cell-cycle inhibitory function of this protein. This mutation gives further support to the premise that ARF is an independent melanoma predisposition gene to CDKN2A that maps to chromosome 9p. Taken together, these findings also implicate inactivation of p14ARF, rather than p16, in susceptibility to NSTs. Genetics of melanoma predisposition NK Hayward
Existence of other potential high-penetrance genes
The CDKN2A and CDK4 genes account for predisposition in less than half of all multiplex melanoma families. Clearly, additional cutaneous melanoma predisposition genes are likely to exist. Moreover, there have, to date, been no families containing cases of both cutaneous and ocular melanoma, or ocular melanoma alone, in which CDKN2A or CDK4 mutations have been found. Thus a major locus for susceptibility to ocular melanoma (with or without cutaneous melanoma) has yet to been mapped, although it should be noted that occasionally ocular melanoma cases have been found in breast cancer families segregating BRCA2 mutations, and a very small proportion of sporadic ocular melanoma cases have also been shown to have mutations of this gene (Easton et al., 1997; Sinilnikova et al., 1999; Iscovich et al., 2002) .
Another potential reservoir for the identification of novel melanoma susceptibility genes is the Ashkenazim. No Ashkenazi family has been reported to have a mutation in either CDKN2A or CDK4 (Yakobson et al., 2000) . Considering the common founder mutations identified in this population in other cancer predisposition genes (e.g. BRCA1 and BRCA2), it is quite likely that a recurrent mutation in an as yet unidentified gene is responsible for familial clustering of melanoma in the Ashkenazim.
The International Melanoma Genetics Consortium is currently carrying out genome-wide scans to localize genes predisposing to cutaneous melanoma, ocular plus cutaneous melanoma and ocular melanoma alone. The results of these studies are eagerly anticipated.
Low-penetrance genes
MC1R
The major host factors associated with melanoma are increased numbers of banal or atypical melanocytic nevi (Elwood et al., 1990; Tucker et al., 1997) , hair colour, eye colour, extent of freckling and skin type (Bliss et al., 1995) . A seminal finding that later led to confirmation of the first low-penetrance susceptibility gene for melanoma was the association of variants of the melanocortin 1 receptor gene (MC1R) with red hair and fair skin (Valverde et al., 1995) . MC1R encodes the G-proteincoupled receptor for a-melanocyte stimulating hormone (a-MSH). Binding of a-MSH to MC1R normally results in activation of adenylate cyclase and an increase in cAMP production, which leads to a switch in melanin production from the red/yellow pheomelanin pigments to the brown/black eumelanins (reviewed in Sturm et al., 1998) . Variants of MC1R appear to be compromised in their capability of inducing this switch in melanin production (i.e. tanning response). Harding et al. (2000) have shown that there is considerable variation of the MC1R gene in European and Asian populations, but very little variation (only silent amino-acid changes) in African populations, indicating the enormous evolutionary pressure in Africa against deviation from eumelanin production.
In a sample of British or Irish Caucasians, Valverde et al. (1995) reported that 53% of individuals with red hair were found to carry one variant allele and 29% had two variant MC1R alleles. In contrast, no individual with any other hair colour was found to carry two variants and overall the frequency of heterozygous carriers of a variant allele in those with blond, brown or black hair did not exceed 33%. Similarly, the majority of individuals (76.5%) with skin type I (very fair skin) carried a variant MC1R allele, whereas no individuals with skin type IV (dark skin) possessed a variant. The frequencies were intermediate for individuals with skin types II (46.5%) and III (5%). Box et al. (1997) confirmed and extended this work and showed that three particular variants of MC1R (R151C, R160W, D294H) were most significantly associated with red hair and fair skin. Furthermore, we (Palmer et al., 2000) and others have shown that the MC1R gene is associated with freckling. Heterozygous carriers of MC1R variants have a 2-3-fold increased risk of developing freckles, an effect that persists after adjustment for hair colour and skin type.
Given the associations between red hair, fair skin, freckling and melanoma risk it is not surprising therefore that certain variants of MC1R have been found to increase risk of cutaneous melanoma. In the first study to report such an association Valverde et al. (1996) compared MC1R genotype between 43 melanoma cases and 44 controls. They found that MC1R variants were significantly more common in cases than controls (P ¼ 0.0094) and conferred a 3.9-fold risk to carriers (95% CI: 1.48-10.35). The bulk of this increased risk in the melanoma group was associated with the D84E variant, which was identified in 10/44 cases, with two individuals being homozygous for this substitution.
In a subsequent study (Ichii-Jones et al., 1998) in which only three variants (D84E, V92M and D294H) were assessed in 306 melanoma cases and 190 controls, allele frequencies were not significantly different between the two groups. However, this lack of association appears to be because of the failure to type some of the most important variants. This notion was borne out in a much larger study (Palmer et al., 2000) , which analysed six variants of MC1R in 460 melanoma patients and 399 population controls. The three major 'red hair colour' variants (R151C, R160W and D294H) were found to each give a 2.2-fold increased risk of melanoma (95% CI: 1.6-3.0). Moreover, this effect was additive (or multiplicative) since individuals with two variants had a 4.1-fold (95% CI: 2.1-7.9) relative risk of melanoma. After adjusting for hair colour and skin type this risk gradient was abolished in those with fair skin but persisted in individuals with medium (OR 2.2; 95% CI: 1.2-4.1) or olive/dark (OR 10.8; 95% CI: 1.2-95.6) complexion. The latter indicates a significant risk conferred by MC1R variants even in those who have dark skin or are able to tan well. Very similar findings were reported by Kennedy et al. (2001) who analysed 123 patients and 385 control subjects. One variant allele was found to give a 2.9-fold risk (95% CI: 1.6-5.4) of melanoma, whereas two variants conferred a 4.8-fold (95% CI: 2.5-9.4) relative risk. Notably, the D84E variant was most significantly associated with melanoma (OR 16.1; 95% CI: 2.3-139.0). Once again susceptibility was largely found to be independent of hair colour and skin type.
Thus, in contrast to the high-penetrance mutations conferred by CDKN2A and CDK4, variants of MC1R have proven to be low-penetrance susceptibility alleles for cutaneous melanoma (Valverde et al., 1996; Palmer et al., 2000; Kennedy et al., 2001) . However, in contrast, MC1R variants have not been shown to predispose individuals to uveal melanoma (Metzelaar-Blok et al., 2001).
Other potential low-penetrance genes
CDKN2A polymorphisms
In addition to the obvious impact of clearly inactivating mutations within the CDKN2A gene, the rare alleles at either the C500G (Aitken et al., 1999) or C540T polymorphism (Kumar et al., 2001) in the 3 0 untranslated region of the gene have been significantly associated with risk of developing melanoma. Aitken et al. (1999) showed that the frequencies of the rarer alleles at nucleotide 500 and nucleotide 540 of CDKN2A were higher in 514 melanoma cases compared to 200 controls, being 14.2 versus 11.1% and 10.9 versus 9.5%, respectively (although these values were not significantly different between groups) (Table 4) . However, when the melanoma cases were stratified on the basis of strength of familial risk of melanoma (high-risk ¼ top 2.5 percentile; intermediate risk ¼ top 50 percentile, low risk ¼ bottom 50 percentile), there was a significant trend (P ¼ 0.02) for the C500G polymorphism to increase with increasing familial risk group and was highest in the group that also carried deleterious intragenic mutations of CDKN2A. A similar but nonsignificant trend was also observed for the C540T variant. After adjustment for ethnic origin the relation between the C500G polymorphism and risk group was weakened (P ¼ 0.25), indicating that this effect was, at least in part, because of population stratification, most likely representing predominantly Celtic ancestry in the highest familial risk group. The use of within-family tests such as transmission disequilibrium are needed to clarify the potential association between CDKN2A 3 0 UTR polymorphisms and what might be a relatively weak contribution to melanoma risk. Kumar et al. (2001) analysed the nucleotide 500 and 540 polymorphisms of CDKN2A in 229 melanoma cases and 235 controls and similarly found that the frequency of the rare allele at both positions was higher in the melanoma cases, although it only reached statistical significance (P ¼ 0.01) for the C540T polymorphism (14% in cases versus 8% in controls). The authors estimated that this difference in frequency conferred a 1.7-fold (95% CI: 1.11-2.66) relative risk to carriers of the nucleotide 540 T allele. Further in support of a role for these 3 0 UTR polymorphisms in melanoma development prior work from the same group (Sauroja et al., 2000) had shown that carriers of either of these variants had a significantly (P ¼ 0.007) shorter progression time from diagnosis of the primary tumour to the appearance of metastasis. Moreover, in tumours that showed loss of heterozygosity the variant allele was usually retained.
The mechanism by which these variants could confer melanoma risk is unknown but it is conceivable that these alleles could exert their effect through altering either the stability of the CDKN2A transcript or the level of CDKN2A transcription; or alternatively, these variants might be in linkage disequilibrium with an as yet unidentified variant directly responsible for the increased melanoma susceptibility.
EGF
Recently, Shahbazi et al. (2002) sought to determine whether there existed differences in variants of the epidermal growth factor gene (EGF) between melanoma cases and controls. They considered this gene a reasonable candidate for conferring melanoma risk because of its role in mitogenesis and wound healing. They identified a single-nucleotide polymorphism (SNP) located 382 nucleotides upstream of the initiation codon of preproEGF (Genbank Accession number NM_001963) and found this adenine (A) to guanine (G) substitution appeared responsible for determining the level of EGF produced by peripheral blood mononuclear cells cultured in vitro after stimulation with phorbol myristate acetate and lipopolysaccharide. Cells from individuals homozygous for the G allele produced significantly more EGF than those from individuals homozygous for the A allele (P ¼ 0.0004) or heterozygous for the SNP (P ¼ 0.001). Although the mechanism by which this SNP is related to levels of EGF expression is not known, this functionally relevant polymorphism was also found to be associated with melanoma risk. Overall, the frequency of the G allele was significantly more common in melanoma cases compared with controls (66 versus 44% respectively, Po0.0001). This difference conferred a 2.7-fold relative 2) was associated with homozygosity of the G allele, but there was no significant risk associated with heterozygosity for this polymorphism, although this may have been because of the relatively small numbers of individuals typed (135 cases and 99 controls). There was also a marginally significant association (P ¼ 0.045) between homozygous G genotype and tumours presenting with Breslow thickness of >3.5 mm versus tumours less than 3.5 mm (odds ratio ¼ 3.7; 95% CI, 1.0-13.2). However, this difference was no longer significant when skin type, hair colour and eye colour were included in the logistic regression analysis. Taken together, these results appear to indicate that increased expression of EGF is associated with melanoma predisposition. This potentially highly significant finding clearly warrants validation in a larger sample, with particular attention to minimizing possible population differences because of ethnicity.
GSTM1
About half of the Caucasian population is genotypically null for the glutathione S-transferase gene (GSTM1). Since GSTM1 codes for an enzyme that catalyses the detoxification of various compounds, including potentially carcinogenic epoxides, individuals who lack this gene might be expected to be at increased risk of cancer. Initial studies comparing melanoma cases with controls in the predominantly Anglo-Celtic populations of the United Kingdom and Australia found the same frequency (52%) of GSTM1 nullizygotes in both groups (Heagerty et al., 1994; Shanley et al., 1995) (Table 5 ). In contrast, there was a significantly increased frequency of GSTM1 null phenotype in melanoma cases compared with controls (58 versus 41%, P ¼ 0.002) from a Hospital-based study in Barcelona (Lafuente et al., 1995) . The most noticeable feature of this study was the much lower frequency of nullizygotes in the Spanish controls compared to that observed in other Caucasian control populations. In the most recent study of GST polymorphisms and melanoma risk, Kanetsky et al. (2001) found no significant increase in frequency of either GSTM1 or GSTT1 nullizygotes in the melanoma cohort compared with controls from Pennsylvania. However, when they stratified by pigmentation characteristics they found that among individuals with red or blond hair cases were 2.2-fold more likely (95% CI, 1.2-4.2) than controls to be GSTM1 null, and 9.5-fold more likely (95% CI, 1.2-73.0) to be nullizygous for both GSTM1 and GSTT1. As red/blond hair colour is determined to a large extent by variants of the MC1R locus (discussed above), these findings may indicate that MC1R genotype acts to modify melanoma risk from GST nullizygosity in a manner similar to the way it acts as a modifier of CDKN2A penetrance. It will be interesting to determine whether GSTM1 or GSTT1 genotype similarly affects penetrance of CDKN2A mutations.
CYP2D6
Since cytochrome P450 enzymes have the interesting potential to act in opposing biological ways, namely to either detoxify certain lipophilic compounds or to activate them to carcinogenic forms, polymorphism of cytochrome P450 family members is likely to be associated with genetic susceptibility to a wide variety of cancers, including melanoma. There are three welldocumented inactivating polymorphisms at the cytochrome P450 debrisoquine hydroxylase locus (CYP2D6): gene deletion, a splice site mutation and a nucleotide deletion in the coding region (reviewed in Wolf et al., 1992) . Homozygotes for nonfunctional alleles are termed poor metabolizers and have greatly reduced capacity to metabolize certain chemicals. If CYP2D6 was responsible for activation of various carcinogens then poor metabolizer phenotype would be expected to be associated with reduced cancer susceptibility. Wolf et al. (1992) found no significant difference in the frequency of poor metabolizers between 127 melanoma cases and 720 controls (5.3 versus 4.3%, respectively) in the United Kingdom, although they did observe a significant (P ¼ 0.02) increase in mutant alleles in the melanoma cohort (Table 6 ). The latter finding is most likely because of chance since a larger difference in allele distribution was found when controls recruited from Edinburgh were compared to those from Sheffield. Alternatively, it could indicate that rather than activating certain carcinogens, CYP2D6 is mainly involved in detoxifying potentially carcinogenic compounds. This notion was supported by Strange et al. (1999) , who in a case-control study of individuals of Northern European Caucasian ancestry, comprising 333 melanoma cases and 467 controls, found a significantly higher frequency of mutant alleles (28 versus 21%, P ¼ 0.039) and poor metabolizers in the melanoma cases (10.8 versus 4.5%, P ¼ 0.001). In contrast, Dolzan et al. (1995) found no increase in mutant CYP2D6 alleles in melanoma cases versus Slovene population controls, but rather a Genetics of melanoma predisposition NK Hayward nonsignificantly lower frequency of poor metabolizers in the melanoma cohort (5.0 versus 6.5%). Hutchinson et al. (2000) proposed that the vitamin D receptor gene (VDR) might contribute to melanoma risk since the VDR ligand, calcitriol, has antiproliferative and prodifferentiation effects on melanocytes and melanoma cells, and polymorphisms of this gene have been associated both with serum calcitriol levels and risk of several other types of cancer (reviewed in Hutchinson et al., 2000) . In a case-control study comprising 316 melanoma cases and 108 controls, all of Northern European Caucasian decent, the rarer allele of a Fok I polymorphism, which results in a novel VDR translation start site, was significantly more common in melanoma cases than controls (39.9 versus 31.5%; P ¼ 0.029). This difference is marginal and clearly needs to be validated in a much larger study.
VDR
Modifier genes
MC1R
Interestingly, apart from acting as independent risk factors for melanoma, MC1R variants have also been shown to act as modifier alleles, increasing the penetrance of mutations in CDKN2A van der Velden et al., 2001) . In a study of 15 Australian melanoma families in which nine different CDKN2A mutations were segregating, the presence of an MC1R variant significantly increased (P ¼ 0.01) the raw penetrance of the CDKN2A mutation (i.e. development of melanoma) from 50 to 84% . Moreover, this increase in penetrance was associated with a significant lowering of the mean age of onset from 58.1 years in individuals wild type for MC1R to 37.8 years in those that carried an MC1R variant. The impact of MC1R on melanoma risk was found to be mediated chiefly by the three major 'red hair colour ' variants (R151C, R160W and D294H) . In a synchronous study, van der Velden et al. (2001) assessed the impact of MC1R genotype on melanoma development in 101 carriers of the 'p16-Leiden' mutation of CDKN2A. Raw penetrance of melanoma in MC1R wild-type individuals was 18%, which increased to 35 or 55% in those with one or two variant alleles, respectively (P ¼ 0.01). The R151C variant of MC1R was responsible for the majority of the observed effect on melanoma risk. Interestingly, in this population the increase in raw penetrance was not accompanied by a concomitant reduction in the mean age of onset of melanoma. This observation may be because of differences in the impact of the CDKN2A mutations between studies, or more likely, an added layer of complexity because of a possible effect of differences in ultraviolet radiation (UVR) exposure between the Australian and Dutch cohorts potentially modifying the penetrance of both the CDKN2A and MC1R mutations.
ARF
Data have accumulated recently to indicate that ARF influences penetrance of CDKN2A mutations in mice. Two groups (Krimpenfort et al., 2001; Sharpless et al., 2001) have generated specific knockouts of the murine Ink4a (p16 encoding) gene. Animals from both studies were prone to the development of various tumours, including spontaneous development of melanoma, albeit at a very low frequency. Carcinogen treatment had little effect on melanoma incidence. Interestingly, in the study of Krimpenfort et al. (2001) , when the p16 null mice were crossed with Arf hemizygotes, 50% of the animals developed melanomas after treatment with the carcinogen 7, 12-dimethylbenz(a)anthracene, compared to 8% of the mice lacking just p16. The effect of Arf haploinsufficiency in an Ink4a À/À background suggests cooperation between the p16 and Arf pathways in melanoma development. Thus, Cdkn2a may be involved in melanoma development in mice through mechanisms involving both its Ink4a and Arf transcripts, although the data for such a conclusion in humans are not yet so clear, but is clearly a priority issue to be determined.
Other potential modifier genes
Considering the demonstrated involvement of the MC1R locus as a modifier of melanoma risk in CDKN2A mutation-positive families it seems logical that other pigmentation genes might similarly act as melanoma modifier loci. From determining the human orthologs of various mouse coat colour genes, as well as the identification of genes responsible for different forms of oculocutaneous albinism, a large number of genes that play a role in pigmentation are beginning to emerge. Very recently, variation in ASIP, the gene encoding agouti signalling protein, a second ligand of MC1R and an antagonist of a-MSH, was found to be associated with normal human pigmentation (Kanetsky et al., 2002) . The rare allele of a polymorphism in the 3 0 UTR of the gene was found to be significantly associated with dark hair (OR 1.8; 95% CI 1.2-2.8) and brown eyes (OR 1.9; 95% CI 1.3-2.8). However, in this study, comparison of 423 melanoma cases and 147 controls showed no contribution of the ASIP polymorphism to melanoma susceptibility. Still, other pigmentation genes, for example, TYR, TYRP1, TYRP2, P, UW, KIT (reviewed in Sturm et al., 2001) , remain as good candidates, both as low-risk melanoma predisposition genes as well as modifier genes. Other classes of genes, such as those encoding DNA repair enzymes or enzymes involved in carcinogen metabolism similarly make rational candidates.
Environmental modifiers
UVR
Epidemiologic studies suggest that exposure to sunlight is the major environmental risk factor for melanoma, although the exposure-response relation appears complex (reviewed in Armstrong and English, 1996) . Thus, differences in relative exposure to UVR by latitude may contribute to the wide geographic variation in melanoma incidence rates. In Australia, annual agestandardized melanoma incidence rates in 1992-1996 varied between regions from 33 to 63 per 100 000 for males and 28 to 46 per 100 000 for females (Australian Institute of Health and Welfare, 1999) . In the USA the overall annual age-standardized incidence rate per 100 000 people in 1994 was 19.6 for males and 12.6 for females (Ries et al., 2002) ; the rates in the UK were 3.9 for males and 6.8 for females in 1983 -1987 (Anonymous, 1992 .
The International Melanoma Genetics Consortium recently set out to assess potential geographical variation in the penetrance of CDKN2A mutations in melanoma families from different continents. Families were included in the analysis if each had at least two cases of cutaneous malignant melanoma in first-degree relatives and a proven germline mutation in CDKN2A present in at least one family member. The average lifetime risk conferred by CDKN2A mutations was estimated to be B70%, but showed significant variation from region to region (Bishop et al., 2002) . These data suggest that UVR increases the penetrance of CDKN2A mutations since penetrance is higher in Australia than in the USA and the USA is higher still than Europe (Bishop et al., 2002) .
This study found that gender and coincident mutation affecting p14ARF did not significantly influence penetrance within or between geographical regions, although there was a general trend for penetrance overall to be higher in those families that carried mutations that affected both p14ARF and p16, compared to those that solely abrogated p16 function. A larger study is clearly needed in order to establish the possible inter-relation between p16 and p14ARF on penetrance of melanoma (and possibly other tumour types).
The mechanism by which UVR increases penetrance of CDKN2A mutations is not known. While it may simply reflect an increased mutational burden that would lead to a higher probability of accumulating sufficient additional mutations required for cancer to develop, it is interesting to contemplate whether a more direct mechanism may also play a role since UVR has been shown to induce p16 expression in human skin (Pavey et al., 1999) , where it is involved in a UVRinduced G2 phase cell-cycle block (Pavey et al., 2001) . Additionally, there is a tantalizing but not fully understood link to MC1R, since a-MSH has been shown to potentiate p16 expression in human skin after UVR treatment (Pavey et al., 2002) .
Conclusions
Melanoma is genetically heterogeneous. To date, two high-penetrance and one low-penetrance susceptibility genes have been identified. One genetic modifier and one environmental modifier have also been established. Further characterization of genes contributing to melanoma predisposition will increase our understanding of which individuals in susceptible populations are most at risk, how that risk can be modified and how that knowledge could be used for targeted surveillance, better recognition of early-stage disease and ultimately in the design of improved treatment strategies to reduce melanoma-associated morbidity and mortality.
